Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156


Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.

Plosker GL, Lyseng-Williamson KA.

Pharmacoeconomics. 2007;25(12):1031-53. Review.


A systematic review and economic evaluation of statins for the prevention of coronary events.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.


Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.

Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA.

Health Technol Assess. 2000;4(29):1-123. Review.


The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.


Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.

Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW, Orhewere M, Gisbert J, Sharma VK, Rostom A, Moayyedi P, Forman D.

Health Technol Assess. 2007 Dec;11(51):iii-iv, 1-164. Review.


Hormonal therapies for early breast cancer: systematic review and economic evaluation.

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.


A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.

Buxton M, Caine N, Chase D, Connelly D, Grace A, Jackson C, Parkes J, Sharples L.

Health Technol Assess. 2006 Aug;10(27):iii-iv, ix-xi, 1-164. Review.


Moving toward new statin guidelines in a post-JUPITER world: principles to consider.

Ridker PM.

Curr Atheroscler Rep. 2009 Jul;11(4):249-56. Review.


Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study.

Wu O, Robertson L, Twaddle S, Lowe GD, Clark P, Greaves M, Walker ID, Langhorne P, Brenkel I, Regan L, Greer I.

Health Technol Assess. 2006 Apr;10(11):1-110. Review.


Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.

Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, Smith WC, Jung RT, Campbell MK, Grant AM.

Health Technol Assess. 2004 May;8(21):iii-iv, 1-182. Review.


Cost effectiveness of statins in coronary heart disease.

Franco OH, Peeters A, Looman CW, Bonneux L.

J Epidemiol Community Health. 2005 Nov;59(11):927-33. Review.


Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.


The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.


Intensive statin therapy for Indians: Part-I. Benefits.

Enas EA, Pazhoor HC, Kuruvila A, Vijayaraghavan K.

Indian Heart J. 2011 May-Jun;63(3):211-27. Review.


The JUPITER trial: How will it change clinical practice?

Watson KE.

Rev Cardiovasc Med. 2009 Spring;10(2):91-6. Review.


Effectiveness of statin therapy in adults with coronary heart disease.

Wilt TJ, Bloomfield HE, MacDonald R, Nelson D, Rutks I, Ho M, Larsen G, McCall A, Pineros S, Sales A.

Arch Intern Med. 2004 Jul 12;164(13):1427-36. Review.


Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.


The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines.

Mora S, Musunuru K, Blumenthal RS.

Clin Chem. 2009 Feb;55(2):219-28. doi: 10.1373/clinchem.2008.109728. Epub 2008 Dec 18. Review.

Items per page

Supplemental Content

Write to the Help Desk